- Report
- February 2024
- 250 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- April 2024
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- January 2021
- 600 Pages
United States
From €2703EUR$2,800USD£2,318GBP
- Report
- October 2020
- 222 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Report
- March 2018
- 255 Pages
Global
From €2510EUR$2,600USD£2,153GBP
- Report
- November 2022
- 200 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Report
- April 2023
- 500 Pages
Global
From €3619EUR$3,750USD£3,105GBP
- Clinical Trials
- November 2020
- 40 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Report
- February 2020
- 94 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- April 2022
- 135 Pages
Global
From €4295EUR$4,450USD£3,684GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- April 2023
- 129 Pages
Global
€4826EUR$5,000USD£4,140GBP
- Clinical Trials
- September 2018
- 700 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Report
- June 2023
- 92 Pages
Global
From €3500EUR$3,884USD£3,107GBP
Sipuleucel-T is a type of immunotherapy drug used to treat prostate cancer. It is a personalized cellular therapy, meaning it is made from a patient's own immune cells. The drug works by stimulating the patient's immune system to recognize and attack prostate cancer cells. It is administered through a series of three intravenous infusions over the course of several weeks.
Sipuleucel-T is approved by the U.S. Food and Drug Administration (FDA) for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. It is the only FDA-approved immunotherapy for prostate cancer.
The market for Sipuleucel-T is relatively small, as it is only approved for a specific type of prostate cancer. However, it is an important treatment option for patients with this type of cancer.
Companies in the Sipuleucel-T market include Dendreon Corporation, which manufactures the drug, as well as other pharmaceutical companies that market and distribute it. Show Less Read more